search
Back to results

The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery (AIR)

Primary Purpose

Pancreatic Neoplasms, Urogenital Neoplasm, Systemic Inflammatory Response Syndrome

Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
5% Albumin infusion 30 min
5% Albumin infusion 3 hours
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Neoplasms

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. The patient is scheduled for non-emergent Whipple operation or major gynaecological cancer surgery.
  2. Indication for fluid therapy as judged by the anaesthesiologist in charge and at least one at least one of the following criteria is fulfilled:

    • Positive "leg raising test" (pulse pressure increase > 9% or stroke volume increase by more than 10% as measured with cardiac ultrasound.
    • Central venous oxygen saturation (ScvO2) < 70%.
    • Plasma lactate > 2.0 mmol/l.
    • Urine output < 0.5 ml / kg for the latest hour.
    • Respiratory variation of the inferior vena cava of more than 15% as measured by ultrasound.
    • Systolic pressure < 100 mmHg, mean arterial pressure < 55 mmHg
  3. Age 40 and above
  4. Written consent by patient to participate in the study

Exclusion Criteria:

  1. Hypersensitivity to the active drug/ the tracer.
  2. Signs of postoperative bleeding.
  3. History of heart failure.
  4. The responsible physician considers that there are strong reasons to administrate another fluid or same fluid but in another way or in a different volume than those included in the protocol.
  5. Pregnancy
  6. Clinical judgment by the investigator or the treating physician that the patient should not participate in of the study for reasons other than described above.

Sites / Locations

  • Skåne University Hospital, Region Skåne

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

5% Albumin infusion 30 min

5% Albumin infusion 3 hours

Arm Description

Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.

Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight

Outcomes

Primary Outcome Measures

Change in plasma volume

Secondary Outcome Measures

Change in plasma volume over time
Integral of plasma volume over time
Incidence of postoperative complications

Full Information

First Posted
March 31, 2016
Last Updated
April 18, 2017
Sponsor
Region Skane
search

1. Study Identification

Unique Protocol Identification Number
NCT02728921
Brief Title
The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
Acronym
AIR
Official Title
The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To study if plasma volume expansion is influenced by the rate at which a colloidal solution is administered in patients with a systemic inflammatory response induced by major abdominal surgery. Randomization will be performed postoperatively at the day of surgery with a 1:1 ratio with no stratification and the study drug will be given as a slow (3 hours) or rapid (30 minutes) intravenous infusion.
Detailed Description
Major surgery is one of many triggers of a systemic inflammatory response syndrome (SIRS), which disrupts the normal regulation of transcapillary fluid exchange with tissue oedema and hypovolemia as a consequence. Hypovolemia will amplify the inflammatory reaction by reducing cardiac output and oxygen delivery, which creates a vicious circle. Fluid therapy is therefore a cornerstone in the perioperative treatment patients subjected to major surgery. However, even if fluid therapy is life saving it is also associated with side effects such as further oedema formation, coagulopathy and further endothelial dysfunction. From a clinical perspective, it is therefore important that the fluid administered to antagonize hypovolemia as far as possible remains intravascularly. Colloids are macromolecules for which the vessel wall has a low permeability and proponents of colloid containing fluids argues that less volume is required for equal plasma volume compared to crystalloids. However, extravasation of colloids is not only a function of the vessel wall permeability but is also dependent on the volume of fluid to that is filtered across the vascular wall, which in turn depends on the trans-capillary hydrostatic pressure. This means that administration of colloids in a way that minimizes the increase in capillary pressure could be important for the plasma volume expanding effect. In support of this hypothesis is the experimental result that the plasma volume expansion of a colloidal solution can be affected by the rate of administration (Bark et al., 2013). If this finding proves to be valid also in a clinical setting, it will be very important for how colloidal solutions are prescribed in the clinic and may change current clinical practice in which suspected hypovolemia often is treated with a bolus infusion of fluid. This study intend to investigate whether these findings can be reproduced after a so-called Whipple's operation or after major gynaecological cancer surgery. Study patients will be studied after these procedures because because they are large and standardized operations that trigger an inflammatory condition with capillary leakage and therefore can be considered as a model for major surgical procedures as well as ICU patients with SIRS triggered by for example sepsis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Neoplasms, Urogenital Neoplasm, Systemic Inflammatory Response Syndrome, Hypovolemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
5% Albumin infusion 30 min
Arm Type
Active Comparator
Arm Description
Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
Arm Title
5% Albumin infusion 3 hours
Arm Type
Experimental
Arm Description
Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
Intervention Type
Drug
Intervention Name(s)
5% Albumin infusion 30 min
Intervention Description
Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
Intervention Type
Drug
Intervention Name(s)
5% Albumin infusion 3 hours
Intervention Description
Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
Primary Outcome Measure Information:
Title
Change in plasma volume
Time Frame
From start of infusion until 3 hours after start of infusion
Secondary Outcome Measure Information:
Title
Change in plasma volume over time
Description
Integral of plasma volume over time
Time Frame
From start of infusion until 3 hours after start of infusion
Title
Incidence of postoperative complications
Time Frame
30 days postoperatively
Other Pre-specified Outcome Measures:
Title
Transcapillary escape rate (TER) for albumin
Time Frame
180-240 min after start of infusion
Title
Change in heart rate, change in central venous oxygen saturation, change in haemoglobin concentration in blood, change in blood pressure, change in central venous pressure, change in plasma lactate and diuresis.
Time Frame
From start of infusion until 3 hours after start of infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient is scheduled for non-emergent Whipple operation or major gynaecological cancer surgery. Indication for fluid therapy as judged by the anaesthesiologist in charge and at least one at least one of the following criteria is fulfilled: Positive "leg raising test" (pulse pressure increase > 9% or stroke volume increase by more than 10% as measured with cardiac ultrasound. Central venous oxygen saturation (ScvO2) < 70%. Plasma lactate > 2.0 mmol/l. Urine output < 0.5 ml / kg for the latest hour. Respiratory variation of the inferior vena cava of more than 15% as measured by ultrasound. Systolic pressure < 100 mmHg, mean arterial pressure < 55 mmHg Age 40 and above Written consent by patient to participate in the study Exclusion Criteria: Hypersensitivity to the active drug/ the tracer. Signs of postoperative bleeding. History of heart failure. The responsible physician considers that there are strong reasons to administrate another fluid or same fluid but in another way or in a different volume than those included in the protocol. Pregnancy Clinical judgment by the investigator or the treating physician that the patient should not participate in of the study for reasons other than described above.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Bentzer, MD
Organizational Affiliation
Region Skåne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skåne University Hospital, Region Skåne
City
Lund
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data collected in the current study will be available from the corresponding author on reasonable request.
Citations:
PubMed Identifier
27923389
Citation
Statkevicius S, Bonnevier J, Bark BP, Larsson E, Oberg CM, Kannisto P, Tingstedt B, Bentzer P. The importance of albumin infusion rate for plasma volume expansion following major abdominal surgery - AIR: study protocol for a randomised controlled trial. Trials. 2016 Dec 7;17(1):578. doi: 10.1186/s13063-016-1714-5.
Results Reference
derived

Learn more about this trial

The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery

We'll reach out to this number within 24 hrs